Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib

Lung Cancer

Volumn 73, Issue 2, 2011, Pages 211-216

  Asami, Kazuhiro ^a   Kawahara, Masaaki ^b   Atagi, Shinji ^a   Kawaguchi, Tomoya ^a   Okishio, Kyoichi ^a  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b OTEMAE HOSPITAL   (Japan)

Author keywords

EGFR mutation; Erlotinib; Gefitinib; Resistance to EGFR TKIs; Time to progression of gefitinib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE DELETION; HUMAN; LUNG ADENOCARCINOMA; MALE; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THERAPY DELAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE;

EID: 79960066208     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.12.014     Document Type: Article

References (23)

1. Moscatello D.K., Holgado-Madruga M., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55(23):5536-5539.
2. Janne P.A., Engelman J.A., et al. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005, 23(14):3227-3234.
3. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23(11):2445-2459.
4. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004, 101:13306-13311.
5. Mitsudomi T., Kosaka T., Endoh H., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23(11):2513-2520.
6. Mok T.S., Wu Y.-L., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(September (10)):947-957.
7. Shepherd F.A., Rodrigues Pereira J., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
8. Johnson J.R., Cohen M., et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005, 11(18):6414-6421.
9. Allan S., et al. Efficacy of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) relative to clinical characteristics: subset analysis from the TRUST study. Poster presented at ASCO 2008.
10. Baselga J., Rischin D., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20(November (21)):4292-4302.
11. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19(July (13)):3267-3279.
12. Riely G.J., Pao W., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12(3 (Pt 1)):839-844.
13. Choong N.W., Dietrich S., Seiwert T.Y., Tretiakova M.S. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006, 3(January (1)):50-57. [quiz 1 p following 57].
14. Mitsudomi T., Kosaka T., Endoh H., Yoshida K. Mutational analysis of the EGFR gene in lung cancer with acquired resistance to gefitinib. J Clin Oncol 2006, 24(18S):7074.
15. Pao W., Balak M.N., Riely G.J., Li A.R. Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. J Clin Oncol 2006, 24(18S):7078.
16. Bean J., Brennan C., Shih J.Y., Riely G., Viale A. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104(December (52)):20932-209327.
17. Engelman J.A., Zejnullahu K., Mitsudomi T. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(May (5827)):1039-1043.
18. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(May (5827)):1039-1043. [Epub 2007 April 26].
19. Balak M.N., Gong Y., Riely G.J., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12(Nov (21)):6494-6501.
20. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18(10):2095-2103.
21. Costa D.B., Schumer S.T., Tenen D.G., et al. Differenctial responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008, 26(7):1182-1184.
22. Yoshimasu T., Ohta F., Oura S., et al. Histoculture drug response assay for gefitinib in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 2009, 57(March (3)):138-143. [Epub 2009 March 12].
23. Clarke J.L., Pao W., Wu N., et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010, February.